Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Capital Leases (2016 - 2018)

Wave Life Sciences' Capital Leases history spans 4 years, with the latest figure at $9.2 million for Q4 2018.

  • For Q4 2018, Capital Leases rose 198.87% year-over-year to $9.2 million; the TTM value through Dec 2018 reached $9.2 million, up 198.87%, while the annual FY2018 figure was $9.2 million, 198.87% up from the prior year.
  • Capital Leases reached $9.2 million in Q4 2018 per WVE's latest filing, up from $8.2 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $9.2 million in Q4 2018 to a low of $16000.0 in Q4 2016.
  • Average Capital Leases over 4 years is $2.6 million, with a median of $1.6 million recorded in 2017.
  • Peak YoY movement for Capital Leases: plummeted 79.49% in 2016, then surged 19237.5% in 2017.
  • A 4-year view of Capital Leases shows it stood at $78000.0 in 2015, then tumbled by 79.49% to $16000.0 in 2016, then soared by 19237.5% to $3.1 million in 2017, then surged by 198.87% to $9.2 million in 2018.
  • Per Business Quant, the three most recent readings for WVE's Capital Leases are $9.2 million (Q4 2018), $8.2 million (Q3 2018), and $6.5 million (Q2 2018).